Sionna Therapeutics reported topline results from a Phase 2a cystic fibrosis trial of SION-719 added to Trikafta.
The study failed to show the intended clinical activity, prompting the company to stop pursuing SION-719 as an add-on therapy.
Management is reviewing trial confounders to guide next steps for its SION-451 dual-combination program.
SION-451 combination study and cash position
Separately, a Phase 1 healthy-volunteer study of SION-451 combinations met safety and drug-exposure objectives, with SION-451 plus SION-2222 selected as the preferred regimen.
The company ended Q2 with about $268.3 million in cash, outlining plans to preserve capital while it reassesses development priorities.
SION•
